Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 5/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17059047 | 0.98 | ALDH1A1 (0.56) | ALDH1A1TP53TSHRCYP3A4CES2 | |
| SCHEMBL8465387 | 0.91 | TSHR (0.61) | ALDH1A1TP53TSHRCES2MEN1 | |
| SCHEMBL8877230 | 0.91 | TSHR (0.61) | ALDH1A1TP53TSHRCES2MEN1 | |
| SCHEMBL5165951 | 0.91 | TSHR (0.61) | ALDH1A1TP53TSHRCES2MEN1 | |
| SCHEMBL11688123 | 0.91 | TSHR (0.61) | ALDH1A1TP53TSHRCES2MEN1 | |
| SCHEMBL27272346 | 0.91 | TSHR (0.64) | ALDH1A1TP53TSHRCYP3A4CES2 | |
| SCHEMBL13986867 | 0.87 | TSHR (0.68) | ALDH1A1TP53TSHRCES2MEN1 | |
| SCHEMBL15883090 | 0.86 | — | — | |
| SCHEMBL26312626 | 0.84 | TSHR (0.52) | ALDH1A1TP53TSHRCYP3A4CES2 | |
| SCHEMBL26247220 | 0.84 | TSHR (0.52) | ALDH1A1TP53TSHRCYP3A4CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113388007-A | Ultra-pure agonists of guanylate cyclase C, methods of making and using the same | 博士医疗爱尔兰有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-105764916-B | Ultra-pure agonists of guanylate cyclase C, methods of making and using the same | 博士医疗爱尔兰有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-20160257695-A1 | SYNTHESIS OF SUBSTITUTED SALICYLALDEHYDE DERIVATIVES | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2016-09-08 | — | — | US | disclosed |
| CN-102858361-B | Agonists of guanylate cyclase for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstones, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2016-08-03 | — | — | CN | disclosed |
| US-9371334-B2 | Synthesis of substituted salicylaldehyde derivatives | NOVOMER, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150011761-A1 | SYNTHESIS OF SUBSTITUTED SALICYLALDEHYDE DERIVATIVES | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2015-01-08 | — | — | US | disclosed |
| US-8859822-B2 | Synthesis of substituted salicylaldehyde derivatives | NOVOMER, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130197223-A1 | SYNTHESIS OF SUBSTITUTED SALICYLALDEHYDE DERIVATIVES | NOVOMER, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2012040454-A2 | SYNTHESIS OF SUBSTITUTED SALICYLALDEHYDE DERIVATIVES | NOVOMER, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| CN-100503600-C | Heterocyclic pesticides | BAYER CROPSCIENCE AG (DE) | 2009-06-24 | — | — | CN | disclosed |
| CN-101070317-A | Heterocyclic derivatives, composition containing same and method for pests control | FMC CORP (US) | 2007-11-14 | — | — | CN | disclosed |
| CN-1692108-A | Heterocyclic pesticides | FMC CORP (US) | 2005-11-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257695-A1 | SYNTHESIS OF SUBSTITUTED SALICYLALDEHYDE DERIVATIVES | ADSL, ALDH3A1, SUCLA2 | ALDH1A1 55/4885TP53 2595/4885TSHR 3971/4885 |
| US-20150011761-A1 | SYNTHESIS OF SUBSTITUTED SALICYLALDEHYDE DERIVATIVES | ADSL, ALDH3A1, SUCLA2 | ALDH1A1 55/4885TP53 2595/4885TSHR 3971/4885 |
| US-20130197223-A1 | SYNTHESIS OF SUBSTITUTED SALICYLALDEHYDE DERIVATIVES | ADSL, ALDH3A1, SUCLA2 | ALDH1A1 55/4885TP53 2595/4885TSHR 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.